Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Meridian's MDx Test for Group B Strep

NEW YORK (GenomeWeb News) – Meridian Bioscience today announced the US Food and Drug Administration has cleared its molecular diagnostic test for Group B Streptocococcus (GBS).

The clearance is the second for a Meridian MDx test that runs on its illumigene platform, following FDA clearance of the Cincinnati-based firm's test for C.difficile in June 2010.

According to the company, Strep B is a major perinatal pathogen for both mothers and infants, and the GBS test allows laboratories to comply with recommendations from the Centers for Disease Control and Prevention calling for universal culture-based screening to be performed at 35 to 37 weeks of gestation.

The test, Meridian said, has a simplified workflow and increased sensitivity "for early diagnosis and proper management." Using loop-mediated isothermal DNA amplification technology, the GBS test can yield results in less than one hour.

"The new test begins the expansion of the illumigene platform and provides a molecular technology that is affordable, simple, and quick," Richard Eberly, COO of Meridian, said in a statement.

In its fourth-quarter earnings release last month the company said that it plans launches later this year of its illumigene Mycoplasma pneumonia, illumigene Group A Strep, and illumigene Pertussis for whooping cough tests.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.